Who are Chemotherapy plus monoclonal antibody's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Experimental: mXELOX plus cetuximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chemotherapy-plus-monoclonal-antibody.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Chemotherapy plus monoclonal antibody — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotherapy plus monoclonal antibody (Chemotherapy plus monoclonal antibody) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy plus monoclonal antibody. Area: Oncology.

phase 2 Chemotherapy plus monoclonal antibody Oncology Biologic Live · refreshed every 30 min

Target snapshot

Chemotherapy plus monoclonal antibody (Chemotherapy plus monoclonal antibody) — Grupo Espanol Multidisciplinario del Cancer Digestivo. Chemotherapy plus monoclonal antibody works by targeting cancer cells with a combination of chemotherapy agents and monoclonal antibodies that specifically bind to and destroy cancer cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chemotherapy plus monoclonal antibody TARGET	Chemotherapy plus monoclonal antibody	Grupo Espanol Multidisciplinario del Cancer Digestivo	phase 2	Chemotherapy plus monoclonal antibody
Experimental: mXELOX plus cetuximab	Experimental: mXELOX plus cetuximab	Chinese Academy of Medical Sciences	phase 3	Combination chemotherapy plus monoclonal antibody	EGFR (cetuximab component); DNA synthesis (capecitabine/oxaliplatin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy plus monoclonal antibody class)

Grupo Espanol Multidisciplinario del Cancer Digestivo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chemotherapy plus monoclonal antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/chemotherapy-plus-monoclonal-antibody. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab